ArticleAnnals of intensive care2023
Intermittent body composition analysis as monitoring tool for muscle wasting in critically ill COVID-19 patients.
Article in Annals of intensive care, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 11 citations in OpenAlex.
- Muscle mass in critically ill patients: analysis using ultrasound, traditional bioelectrical impedance analysis, and wearable devices: a prospective observational study.European journal of medical research · 2026Article
- Concordance between single-slice abdominal computed tomography-based and bioelectrical impedance-based analysis of body composition in a prospective study.European radiology · 2025Article
- AI-driven body composition monitoring and its prognostic role in mCRPC undergoing lutetium-177 PSMA radioligand therapy: insights from a retrospective single-center analysis.EJNMMI research · 2025Article
- Disease entity impacts muscle wasting in the ICU with COVID-19 patients losing muscle nearly twice as fast.Scientific reports · 2025Article
- The extent of Skeletal muscle wasting in prolonged critical illness and its association with survival: insights from a retrospective single-center study.BMC anesthesiology · 2025Article
- Observational
- Quantification of muscle recovery in post-ICU patients admitted for acute pancreatitis: a longitudinal single-center study.BMC anesthesiology · 2024Article
- Opportunistic screening for long-term muscle wasting in critically ill patients: insights from an acute pancreatitis cohort.European journal of medical research · 2024Article
- Acute muscle wasting rate assessment and long-term mortality in critically ill trauma.Asia Pacific journal of clinical nutrition · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesSARS-CoV-2 virus infection can lead to acute respiratory distress syndrome (ARDS), which can be complicated by severe muscle wasting. Until now, data on muscle loss of critically ill COVID-19 patients are limited, while computed tomography (CT) scans for clinical follow-up are available. We sought to investigate the parameters of muscle wasting in these patients by being the first to test the clinical application of body composition analysis (BCA) as an intermittent monitoring tool. MATERIALS: BCA was conducted on 54 patients, with a minimum of three measurements taken during hospitalization, totaling 239 assessments. Changes in psoas- (PMA) and total abdominal muscle area (TAMA) were assessed by linear mixed model analysis. PMA was calculated as relative muscle loss per day for the entire monitoring period, as well as for the interval between each consecutive scan. Cox regression was applied to analyze associations with survival. Receiver operating characteristic (ROC) analysis and Youden index were used to define a decay cut-off.
resultsIntermittent BCA revealed significantly higher long-term PMA loss rates of 2.62% (vs. 1.16%, p < 0.001) and maximum muscle decay of 5.48% (vs. 3.66%, p = 0.039) per day in non-survivors. The first available decay rate did not significantly differ between survival groups but showed significant associations with survival in Cox regression (p = 0.011). In ROC analysis, PMA loss averaged over the stay had the greatest discriminatory power (AUC = 0.777) for survival. A long-term PMA decline per day of 1.84% was defined as a threshold; muscle loss beyond this cut-off proved to be a significant BCA-derived predictor of mortality.
conclusionMuscle wasting in critically ill COVID-19 patients is severe and correlates with survival. Intermittent BCA derived from clinically indicated CT scans proved to be a valuable monitoring tool, which allows identification of individuals at risk for adverse outcomes and has great potential to support critical care decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.